Print

Plandai Biotechnology, Inc. (PLPL.OB) Submits Request To South African Legislature To Permit Cannabis Research  
3/25/2014 8:56:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE, WA--(Marketwired - March 24, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced the submission of a request for ministerial dispensation to the Secretary of Parliament of South Africa to permit cannabis research in South Africa for medicinal purposes. Dr. Mario Oriani-Ambrosini, a South African legislator battling terminal cancer, recently introduced legislation to permit medical marijuana research and usage that has generated a groundswell of popular support and led to the formation of The Cancer Treatment Campaign.

Dr. Oriani-Ambrosini, who has incurable cancer of the pleura, has sought inter alia via the Medical Innovations Bill to legalize the medicinal and industrial applications of the cannabis plant. Plandaí and the Cancer Treatment Campaign, together with Dr. Oriani-Ambrosini, are seeking a special ministerial dispensation to pursue methods of delivering a clinical dose of non-psychoactive nano-particle cannabinoid molecules. The proposed collective collaborative research project will be conducted by the universities of Cape Town, Mississippi, Alabama and North West, Potchefstroom, making this a uniquely African-American fight against the world scourge of cancer.

Plandaí's live-plant extraction process recovers phytonutrients from plant material in a mainly nano particle form and rearranges the antioxidants (polyenes) into a format bio-compatible with humans and animals. In addition, through Plandaí's agreement with North West University, South Africa, the company holds the world license to the Pheroid® patented entrapment system to deliver protected Phytofare™ antioxidants to the white blood cells. The result of these two combined technologies is the ability to finally deliver a clinical, pharmaceutical grade dose of cannabinoids to human tissues, thereby unlocking the promise of using natural products to fight many of mankind's most elusive and deadly diseases.

Apart from the well-known medical benefits of cannabis, such as reducing nausea, improving appetite, and reducing anxiety, cannabinoids have shown promise in multiple studies for treating various cancers, epilepsy, pain relief, and in neurological diseases including Alzheimer's, Parkinson's, dementia, and Multiple Sclerosis.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.


Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaíbiotech.com



Help employers find you! Check out all the jobs and post your resume.

//-->